

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.10165 • ASTRAZENECA / ALEXION PHARMACEUTICALS

SECTION 1.2

Description of the concentration

On 31 May 2021, the European Commission (the **Commission**) received a notification of a proposed concentration by which AstraZeneca PLC, a global pharmaceutical company, intends to acquire Alexion Pharmaceuticals Inc., a publicly traded US-based biopharmaceutical company in a cash and stock transaction. The concentration amounts to the acquisition of sole control within the meaning of Article 3(1)(b) EUMR.

The notified concentration gives rise to theoretical overlaps between the Parties' respective limited early stage pipeline assets in Phase II of clinical trials in the EEA, which are being pursued for the potential treatment of renal/immunology and oncology indications.

Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE
Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË

Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.